GILEAD SCIENCES SL

🇪🇸Spain

Country: 🇪🇸Spain

Ownership: -

Established: 1994-01-01

Employees: -

Market Cap: $95.8B

Website: http://www.gilead.com/about/worldwide-operations/europe/spain

Clinical Trials

Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Adolescents

Phase 2

Completed

Conditions: HIV

Interventions: Drug: E/C/F/TAF

First Posted Date: 2014-10-28

Last Posted Date: 2018-11-19

Lead Sponsor: Gilead Sciences

Target Recruit Count: 60

Registration Number: NCT02276612

Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Bictegravir (GS-9883) in Human Immunodeficiency Virus (HIV)-1 Infected Participants

Phase 1

Completed

Conditions: HIV-1 Infection

Interventions: Drug: Placebo
Drug: Bictegravir

First Posted Date: 2014-10-27

Last Posted Date: 2020-11-09

Lead Sponsor: Gilead Sciences

Target Recruit Count: 23

Registration Number: NCT02275065

Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection

Terminated

Conditions: Chronic Hepatitis B

First Posted Date: 2014-10-07

Last Posted Date: 2017-10-03

Lead Sponsor: Gilead Sciences

Target Recruit Count: 241

Registration Number: NCT02258581

Locations: 🇮🇹
IRCCS Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy
🇨🇦
Liver and Intestinal Research Centre, Vancouver, British Columbia, Canada
🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

and more 32 locations

Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma

Phase 2

Terminated

Conditions: Small Lymphocytic Lymphoma
Follicular Lymphoma

Interventions: Drug: Idelalisib
Biological: Rituximab

First Posted Date: 2014-10-07

Last Posted Date: 2019-05-14

Lead Sponsor: Gilead Sciences

Target Recruit Count: 10

Registration Number: NCT02258529

Locations: 🇺🇸
Pacific Shores Medical Group, Long Beach, California, United States
🇺🇸
Prarie Lakes Health Care Systems, Inc., Watertown, South Dakota, United States
🇺🇸
St. Agnes Hospital, Baltimore, Maryland, United States

and more 3 locations

Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma

Phase 1

Terminated

Conditions: Follicular Lymphoma
Chronic Lymphocytic Leukemia
Marginal Zone Lymphoma
Small Lymphocytic Lymphoma

Interventions: Drug: GS-9901

First Posted Date: 2014-10-07

Last Posted Date: 2015-10-19

Lead Sponsor: Gilead Sciences

Target Recruit Count: 7

Registration Number: NCT02258555

Locations: 🇺🇸
Innovative Clinical Research Institute, Whittier, California, United States
🇺🇸
Cancer Center Central Connecticut, Southington, Connecticut, United States
🇺🇸
Lombardi Cancer Center-Georgetown University, Washington, District of Columbia, United States

and more 3 locations

Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory Tract

Phase 2

Completed

Conditions: Respiratory Syncytial Virus

Interventions: Drug: Presatovir
Drug: Placebo

First Posted Date: 2014-10-01

Last Posted Date: 2018-08-06

Lead Sponsor: Gilead Sciences

Target Recruit Count: 189

Registration Number: NCT02254408

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇧🇷
Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
🇧🇷
Hospital Universitario USP, Sao Paulo, Brazil

and more 65 locations

Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract

Phase 2

Completed

Conditions: Respiratory Syncytial Virus Infection

Interventions: Drug: Placebo
Drug: Presatovir

First Posted Date: 2014-10-01

Last Posted Date: 2018-09-24

Lead Sponsor: Gilead Sciences

Target Recruit Count: 60

Registration Number: NCT02254421

Locations: 🇨🇭
University Clinical Basel, Basel, Switzerland
🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States

and more 14 locations

Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic HCV Infection

Phase 2

Completed

Conditions: Hepatitis C Virus Infection

Interventions: Drug: LDV/SOF

First Posted Date: 2014-09-29

Last Posted Date: 2018-11-19

Lead Sponsor: Gilead Sciences

Target Recruit Count: 114

Registration Number: NCT02251717

Development of a Patient-Reported Outcome Measure to Assess Symptoms in Patients With Primary Sclerosing Cholangitis (PSC)

Completed

Conditions: Primary Sclerosing Cholangitis

First Posted Date: 2014-09-25

Last Posted Date: 2016-02-09

Lead Sponsor: Gilead Sciences

Target Recruit Count: 26

Registration Number: NCT02247934

Locations: 🇺🇸
University of Colorado Hospital, Denver Health Medical Center, Aurora, Colorado, United States
🇺🇸
University of Miami Miller School of Medicine - Schiff Center for Liver Diseases, Miami, Florida, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

and more 2 locations

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection

Phase 2

Completed

Conditions: Hepatitis C Virus Infection

Interventions: Drug: LDV/SOF
Drug: RBV

First Posted Date: 2014-09-25

Last Posted Date: 2020-03-02

Lead Sponsor: Gilead Sciences

Target Recruit Count: 226

Registration Number: NCT02249182

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy